Valcyte (active ingredient: valganciclovir hydrochloride) is an antiviral medication indicated for the treatment of cytomegalovirus (CMV) retinitis in patients with acquired immunodeficiency syndrome (AIDS). Due to its unique pharmacological properties and potential for severe adverse reactions, its clinical use must strictly adhere to medication guidelines.
Precautions for the use of valcyte
1. Contraindication Screening
(1) Patients with a known hypersensitivity to valganciclovir or ganciclovir.
(2) Patients currently receiving penicillamine (penicillamine must be discontinued before initiating Valcyte therapy).
(3) Patients with an absolute neutrophil count < 500 cells/μL, a platelet count < 25,000/μL, or hemoglobin < 8 g/dL.
(4) Patients currently using any form of nitrate medications (may cause life-threatening hypotension).
2. Patient Assessment
(1) Hematological Assessment: A complete blood count (CBC) and platelet count must be performed before starting treatment.
(2) Renal Function Assessment: Measure serum creatinine or calculate creatinine clearance (CrCl).
(3) Hepatic Function Assessment: Use with caution in patients with moderate to severe hepatic impairment.
(4) Pregnancy Status: Confirm pregnancy status in women of childbearing age.
(5) Allergy History: Conduct a detailed inquiry about a history of hypersensitivity reactions to valganciclovir or ganciclovir.
3. Management of Drug Interactions
(1) Nephrotoxic Drugs: May increase the risk of nephrotoxicity.
(2) Myelosuppressive Drugs: May exacerbate hematological toxicity.
(3) Probenecid: May increase the plasma concentration of ganciclovir.
(4) Didanosine: May increase the plasma concentration of didanosine and the risk of its associated toxicity.
Medication Monitoring for Valcyte
1. Hematological Monitoring
(1) Complete blood count (including neutrophils, hemoglobin, and platelets): Monitor 1–2 times weekly during the initial phase of treatment, and once monthly after the condition stabilizes.
(2) More frequent monitoring is required for patients with a history of hematological abnormalities or a neutrophil count < 1,000/μL.
2. Renal Function Monitoring
(1) Serum creatinine or CrCl: Monitor once weekly during the initial phase of treatment, and once monthly after the condition stabilizes.
(2) More frequent monitoring is required for patients with renal impairment.
3. Monitoring of Key Adverse Reactions
(1) Hematological Toxicity: Neutropenia (27%), anemia (26%), thrombocytopenia (6%).
(2) Renal Impairment: Elevated serum creatinine (12%).
(3) Gastrointestinal Reactions: Diarrhea (41%), nausea (30%), vomiting (21%).
(4) Neurological Reactions: Headache (22%), peripheral neuropathy (9%), paresthesia (8%).
(5) Ophthalmic Monitoring: Conduct regular ophthalmic examinations to assess the progression of CMV retinitis.
4. Monitoring in Special Populations
(1) Patients with Renal Impairment: Intensify monitoring of renal function and hematological parameters.
(2) Elderly Patients: Renal function may be declined, requiring close monitoring.
(3) Pregnant Patients: If Valcyte use is deemed necessary, closely monitor fetal development.
